Although the significance of the soluble form of the receptor in circulating blood and the mechanisms of sLOX-1 release remain unclear, sLOX-1 appears to be a biomarker for acute coronary syndrome [14,15], for rheumatoid arthritis [16], for rupture of thin-cap fibroatheroma [17], for preeclampsia [18] and an early predictor of the metabolic syndrome [19]. The gene discussed is OLR1; the disease is rheumatoid arthritis.